CARsgen's Satri-cel Granted Priority Review by the NMPA ...Middle East

SHANGHAI, May 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted...

Read More Details
Finally We wish PressBee provided you with enough information of ( CARsgen's Satri-cel Granted Priority Review by the NMPA )

Also on site :

• Sophia Bush and Chris Carmack Trade 2000s Dramas for New Thriller: Watch
• Lightspeed backs Indian home services startup Snabbit as the next big consumer trend
• Pittsburg man sentenced in child sexual abuse material case